Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01516749 · ClinicalTrials.gov registry record · Phase 2

Anakinra as a Treatment for Hydradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT01516749: Completed Phase 2 study of Hidradenitis Suppurativa, sponsored by University of California, San Francisco.

NCT01516749 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01516749, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for relapse of HS.

Primary Outcome

At each study visit, the same physician (dermatologist) examined patients and recorded the following: (i) anatomical regions involved: axilla, groin, gluteal (left ⁄right) or other region, 3 points per region; (ii) numbers and scores of lesions (nodule 1 point, fistula 6 points) for each region; (iii) longest distance between two relevant lesions (or size of single lesion) in each region: \< 5 cm, 1 point; 5-10 cm, 3 points; \> 10 cm, 9 points; and (iv) whether all lesions are separated by norma

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG anakinra

Study Locations (1)

California

  • San Francisco General Hospital - San Francisco

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2012-10
Est. Completion 2013-07
Phase Phase 2
University of California, San Francisco

1,713 total trials

What the finished NCT01516749 record still lists

NCT01516749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which anakinra is the first listed.

NCT01516749 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01516749 about?

NCT01516749 is a clinical study titled "Anakinra as a Treatment for Hydradenitis Suppurativa". This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Th...

What is the current status of trial NCT01516749?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-10. Estimated completion is 2013-07.

What conditions does trial NCT01516749 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT01516749?

The interventions under investigation include: anakinra (DRUG).

Who is sponsoring clinical trial NCT01516749?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01516749 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01516749's enrollment target sits among peer trials

6 53rd of 52 the lowest of 52 other Hidradenitis Suppurativa trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01516749, the US trial registry maintained by the National Library of Medicine. NCT01516749 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.